CHEST Physician
-
Update from the 2025 Council of Networks
Deborah Jo Levine, MD, MS, FCCP, Chair of Council of Networks, shares the highlights that made CHEST 2025 such a huge success for the community on the membership level.
-
Phase 3 IMPALA-2 clinical trial shows inhaled molgramostim promising for autoimmune pulmonary alveolar proteinosis
An ongoing 96-week, open-label period of the trial is designed to shed light on the drug’s long-term safety and efficacy.
-
Oseltamivir found to lower risk of flu-linked neuropsychiatric events in children
This study is the largest and most comprehensive US investigation of the drug and severe neuropsychiatric events, said author James Antoon, MD, PhD, MPH.
-
Data suggest pneumococcal vaccination is underused
Respiratory medicine expert Christina Thornton, MD, PhD, said recent real-world data demonstrate high rates of community-acquired pneumonia driven by serotypes targeted by vaccines.
-
Early data suggest air pollution may initiate lung cancer
Researcher Peiyao Wang said early results show that fine particulate matter is causing permanent DNA damage, which could have implications for lung cancer screening.
-
Making it stick: Rapid pleurodesis for MPE offers faster freedom from IPCs
Rapid pleurodesis combines prompt symptom control with the potential for pleural symphysis in a shorter time frame, allowing for potential lifestyle benefits while minimizing the risk of IPC-related complications.
-
Chest binding and respiratory health in transgender and gender-diverse patients
Clinicians should be educated about chest binding, an important gender-affirming practice for transgender and gender-diverse patients, that can sometimes cause reversible restrictive changes in pulmonary function.
-
Top reads from the CHEST journal portfolio – November 2025
Read new research from the journal portfolio about smoking attitudes and behaviors among patients undergoing lung cancer screening, identification of ARDS subphenotypes, and oxygen saturation targets following cardiac arrest.
-
Osimertinib plus chemo beat chemo alone in patients with advanced EGFR-mutated NSCLC who advanced on first-line osimertinib
Experts said the results of the COMPEL trial support continued treatment with osimertinib beyond progression in this patient population.
-
SOAR Act in limbo while legislators ride out government shutdown
CHEST Past President John E. Studdard, MD, Master FCCP, said the biggest impact of Medicare competitive bidding has been reduced reimbursement, which has slowed innovation in oxygen delivery.
